Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

A RANDOMİZED CONTROLLED TRİAL COMPARİNG THE EFFECTİVENESS OF MYOFASCİAL RELEASE, LOW-LEVEL LASER THERAPY, AND PELOİD THERAPY İN PATİENTS DİAGNOSED WİTH MİLD TO MODERATE CARPAL TUNNEL SYNDROME

12. November 2026 aktualisiert von: RAİKAN BÜYÜKAVCI, Konya Beyhekim Training and Research Hospital

This randomized controlled trial aims to compare the effectiveness of low-level laser therapy (LLLT), myofascial release (MFR), and peloid therapy in patients diagnosed with mild to moderate carpal tunnel syndrome (CTS). A total of 84 eligible participants aged 18-65 years will be randomly assigned to one of three treatment groups. Group 1 (LLLT): Patients will receive low-level laser therapy 5 days a week for 3 weeks (total 15 sessions). Group 2 (Myofascial Release): Patients will receive manual myofascial release therapy 3 days a week for 5 weeks. Group 3 (Peloid Therapy): Patients will receive peloid (mud) therapy at 45°C for 20 minutes, 5 days a week for 3 weeks (total 15 sessions). Clinical evaluations will be performed at baseline, at the end of the treatment (15th session), and at the 12-week follow-up. The primary outcome measures are the Boston Carpal Tunnel Questionnaire (BCTSQ) and Jamar dynamometer grip strength. Secondary outcome measures include ultrasonographic median nerve cross-sectional area (CSA) and electrophysiological nerve conduction studies (EMG).

Studienübersicht

Status

Rekrutierung

Bedingungen

Intervention / Behandlung

Detaillierte Beschreibung

Background and Rationale: Carpal Tunnel Syndrome (CTS) is the most common peripheral nerve entrapment syndrome, resulting from the compression of the median nerve at the wrist. Conservative treatment options play a primary role in the management of mild to moderate CTS, aiming to reduce pain, alleviate symptoms, and improve functional status without immediate surgical intervention. This single-center, randomized controlled trial aims to compare the clinical and objective effectiveness of three distinct conservative modalities-low-level laser therapy (LLLT), myofascial release (MFR), and peloid therapy-routinely used in clinical practice. Study Design and Participants: A total of 84 male and female patients aged 18-65 years diagnosed with mild to moderate CTS at the Department of Physical Medicine and Rehabilitation, SBÜ Konya Beyhekim Training and Research Hospital, will be enrolled. Participants will be randomized into three intervention groups using a computer-generated randomization scheme. Intervention Groups:• Group 1 (Low-Level Laser Therapy - LLLT): Patients will receive LLLT administered by an experienced technician 5 days a week for 3 weeks (15 sessions in total). Treatment will be applied using a gallium-aluminum-arsenide (GaAlAs) diode laser emitting infrared light at an 860 nm wavelength, 1 kHz frequency, and 100 mW power output. The dosage will be 3.6 J/cm2, applied perpendicular to the skin over an area of approximately 15-20 cm2 for 40 seconds, with a total session duration of 120 seconds. • Group 2 (Myofascial Release - MFR): Patients will receive manual myofascial release therapy performed by an experienced physician 3 days a week for 5 weeks (15-30 minutes per session). The intervention will involve identifying tight muscle bands and trigger points in the wrist and forearm, applying direct pressure, gentle stretching, and implementing specific nerve and tendon gliding exercises. • Group 3 (Peloid Therapy): Patients will receive medical peloid therapy (sourced from Köyceğiz, Muğla, rich in organic/inorganic substances and humic acid) applied 5 days a week for 3 weeks (15 sessions in total). A 1.5-2 cm thick layer of peloid heated to 45°C will be applied to the affected extremity, wrapped with a plastic bag and towel for 20 minutes, followed by gentle cleansing with warm water. Outcome Measures and Evaluation Schedule: Evaluations will be performed at baseline, at the end of the treatment (15th session), and at the 12-week follow-up. • Primary Outcome Measures: Symptom severity and functional status assessed via the Boston Carpal Tunnel Questionnaire (BCTSQ), and maximum grip strength measured objectively using a Jamar dynamometer. • Secondary Outcome Measures: Ultrasonographic assessment of the median nerve cross-sectional area (CSA) at the wrist level and electrophysiological nerve conduction studies (EMG) performed at the 12-week control.

Studientyp

Interventionell

Einschreibung (Geschätzt)

88

Phase

  • Unzutreffend

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

  • Name: RAİKAN BÜYÜKAVCI, MD, Prof.
  • Telefonnummer: 4042 +90-0332-224-30-00
  • E-Mail: rsoydemir@yahoo.com

Studienorte

      • Konya, Türkei (türkiye), 42000
        • Rekrutierung
        • University of Health Sciences, Konya Beyhekim Training and Research Hospital

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre bis 65 Jahre (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Ja

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  • Age between 18 and 65 years.
  • Diagnosis of mild or moderate Carpal Tunnel Syndrome (CTS) confirmed by electrophysiological tests (EMG).
  • Symptoms persisting for at least 3 months.
  • No prior history of surgical treatment for carpal tunnel syndrome.

Exclusion Criteria:

  • Severe carpal tunnel syndrome detected by electrophysiological tests.
  • History of severe trauma, fracture, or surgery in the same extremity within the last 6 months.
  • Having received physical therapy (TENS, laser, exercise, etc.) or injection therapy for CTS within the last 3 months.
  • Pregnant or lactating women.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Aktiver Komparator: Low-Level Laser Therapy (LLLT) Group

Patients in this group will receive low-level laser therapy (LLLT) administered 5 days a week for 3 weeks, totaling 15 sessions. The treatment will be applied using a gallium-aluminum-arsenide (GaAlAs) diode laser emitting infrared light.

Low-level laser therapy administered 5 days a week for 3 weeks (total 15 sessions) using a GaAlAs diode laser.

Aktiver Komparator: Myofascial Release (MFR) Group

Patients in this group will receive manual myofascial release (MFR) therapy performed 3 days a week for 5 weeks. The intervention involves identifying tight muscle bands and trigger points in the wrist and forearm, applying direct manual pressure, gentle stretching, and specific nerve and tendon gliding exercises.

Manual myofascial release therapy performed 3 days a week for 5 weeks, including trigger point release and neural/tendon gliding exercises.

Aktiver Komparator: Peloid Therapy Group

Patients in this group will receive medical peloid (mud) therapy applied 5 days a week for 3 weeks, totaling 15 sessions. A 1.5-2 cm thick layer of peloid heated to 45°C will be applied to the affected extremity, wrapped for 20 minutes, and then gently cleansed with warm water.

Medical peloid therapy applied at 45°C for 20 minutes, 5 days a week for 3 weeks (total 15 sessions).

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Boston Carpal Tunnel Questionnaire (BCTSQ) Score
Zeitfenster: Baseline, at the end of treatment (week 3 / 15th session), and at the 12-week follow-up.

Assessment of symptom severity and functional status using the Boston Carpal Tunnel Questionnaire (BCTSQ), which consists of a Symptom Severity Scale (11 items) and a Functional Status Scale (8 items), scored from 1 (best) to 5 (worst).

Baseline, at the end of treatment (week 3 / 15th session), and at the 12-week follow-up.
Maximum Grip Strength
Zeitfenster: Baseline, at the end of treatment (week 3 / 15th session), and at the 12-week follow-up.

Objective measurement of maximum hand grip strength evaluated using a Jamar dynamometer (recorded in kilograms or pounds).

Baseline, at the end of treatment (week 3 / 15th session), and at the 12-week follow-up.

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Ultrasonographic Median Nerve Cross-Sectional Area (CSA)
Zeitfenster: Baseline and at the 12-week follow-up.

Assessment of the median nerve cross-sectional area (CSA) at the wrist level using high-resolution ultrasonography to evaluate structural changes and reduction in nerve swelling.

Baseline and at the 12-week follow-up.
Electrophysiological Nerve Conduction Parameters (SNCV, SNAP, CMAP, DML)
Zeitfenster: Baseline and at the 12-week follow-up.

Evaluation of median nerve conduction characteristics, including sensory nerve conduction velocity (SNCV), sensory nerve action potential (SNAP) amplitude, compound muscle action potential (CMAP) amplitude, and distal motor latency (DML).

Baseline and at the 12-week follow-up.

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Ermittler

  • Hauptermittler: ERDİ İNCİGÜZ, M.D., University of Health Sciences, Konya Beyhekim Training and Research Hospital
  • Studienstuhl: RAİKAN BÜYÜKAVCI, MD, Prof., University of Health Sciences, Konya Beyhekim Training and Research Hospital

Publikationen und hilfreiche Links

Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.

Allgemeine Veröffentlichungen

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

5. März 2026

Primärer Abschluss (Geschätzt)

1. März 2027

Studienabschluss (Geschätzt)

1. Juli 2027

Studienanmeldedaten

Zuerst eingereicht

12. November 2026

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

12. November 2026

Zuerst gepostet (Tatsächlich)

18. November 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

18. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

12. November 2026

Zuletzt verifiziert

1. November 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Andere Studien-ID-Nummern

  • KonyaBeyhekimTRH/01-21

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

JA

Beschreibung des IPD-Plans

Prerequisites / What data will be shared:De-identified individual participant data (including demographic data, baseline and follow-up Boston Carpal Tunnel Questionnaire scores, Jamar grip strength measurements, ultrasonographic median nerve cross-sectional area [CSA] values, and electrophysiological nerve conduction parameters) underlying the results reported in the future publication will be shared.Supporting Documents:Study Protocol and Informed Consent Form will also be available upon request.Time Frame:Available beginning 3 months and ending 5 years following article publication.Access Criteria:Requests should be directed to the corresponding author via email. Data will be shared with researchers whose proposed use of the data has been approved by the principal investigator and institutional ethics committee, provided that a signed data access agreement is established.

IPD-Sharing-Zeitrahmen

Available beginning 3 months and ending 5 years following article publication.

IPD-Sharing-Zugriffskriterien

Requests should be directed to the corresponding author via email. De-identified individual participant data will be shared with researchers whose proposed use of the data has been approved by the principal investigator and institutional ethics committee, upon the establishment of a signed data access agreement.

Art der unterstützenden IPD-Freigabeinformationen

  • STUDIENPROTOKOLL
  • ICF

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .